Dr. Farshid Dayyani
Claim this profileUC Irvine Health/Chao Family Comprehensive Cancer Center
Studies Pancreatic Cancer
Studies Cancer
26 reported clinical trials
55 drugs studied
About Farshid Dayyani
Education:
- Earned an MD from Ludwig Maximilian University of Munich, Germany (Class of 2002).
- Completed Residency in Internal Medicine at Beth Israel Deaconess Medical Center (2006-2008).
- Undertook a Fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center at Houston/MD Anderson Cancer Center (2008-2011).
Experience:
- Serves as Associate Director for Translational Science at UC Irvine Health/Chao Family Comprehensive Cancer Center.
- Holds the position of Medical Director for the Stern Center for Cancer Clinical Trials & Research.
- Appointed Chief of the Division of Hematology/Oncology at UC Irvine School of Medicine.
- Actively involved in clinical trials as Principal Investigator.
Area of expertise
1Pancreatic Cancer
Stage IV
Stage III
HER2 positive
2Cancer
Stage IV
Stage III
HER2 positive
Affiliated Hospitals
Clinical Trials Farshid Dayyani is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Triapine + Targeted Radiation
for Neuroendocrine Cancer
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Recruiting1 award Phase 2
More about Farshid Dayyani
Clinical Trial Related2 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 12 Active Clinical TrialsTreatments Farshid Dayyani has experience with
- Nivolumab
- Irinotecan
- Cabozantinib
- TAS-102
- Docetaxel
- Paclitaxel
Breakdown of trials Farshid Dayyani has run
Pancreatic Cancer
Cancer
Stomach Cancer
Esophageal cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Farshid Dayyani specialize in?
Farshid Dayyani focuses on Pancreatic Cancer and Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Farshid Dayyani currently recruiting for clinical trials?
Yes, Farshid Dayyani is currently recruiting for 12 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Farshid Dayyani has studied deeply?
Yes, Farshid Dayyani has studied treatments such as Nivolumab, Irinotecan, Cabozantinib.
What is the best way to schedule an appointment with Farshid Dayyani?
Apply for one of the trials that Farshid Dayyani is conducting.
What is the office address of Farshid Dayyani?
The office of Farshid Dayyani is located at: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States. This is the address for their practice at the UC Irvine Health/Chao Family Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.